Novel combinatorial approach: Harnessing HIV protease inhibitors to enhance amphotericin B’s antifungal efficacy in cryptococcosis
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0308216 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Nour M Alkashef und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State Univer…. Hauptthemen laut MEDLINE: Amphotericin B, Antifungal Agents, HIV Protease Inhibitors, Drug Synergism. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Cryptococcosis is a fungal infection that is becoming increasingly prevalent worldwide, particularly among individuals with compromised immune systems, such as HIV patients. Amphotericin B (AmB) is the first-line treatment mainly combined with flucytosine. The scarcity and the prohibitive cost of this regimen urge the use of fluconazole as an alternative, leading to increased rates of treatment failure and relapses. Therefore, there is a critical need for efficient and cost-effective therapy to enhance the efficacy of AmB. In this study, we evaluated the efficacy of the HIV protease inhibitors (PIs) to synergize the activity of AmB in the treatment of cryptococcosis. Five PIs (ritonavir, atazanavir, saquinavir, lopinavir, and nelfinavir) were found to synergistically potentiate the killing activity of AmB against Cryptococcus strains with ƩFICI ranging between 0.09 and 0.5 against 20 clinical isolates. This synergistic activity was further confirmed in a time-kill assay, where different AmB/PIs combinations exhibited fungicidal activity within 24 hrs. Additionally, PIs in combination with AmB exhibited an extended post-antifungal effect on treated cryptococcal cells for approximately 10 hrs compared to 4 hours with AmB alone. This promising activity against cryptococcal cells did not exhibit increased cytotoxicity towards treated kidney cells, ruling out the risk of drug combination-induced nephrotoxicity. Finally, we evaluated the efficacy of AmB/PIs combinations in the Caenorhabditis elegans model of cryptococcosis, where these combinations significantly reduced the fungal burden of the treated nematodes by approximately 2.44 Log10 CFU (92.4%) compared to the untreated worms and 1.40 Log10 ((39.4%) compared to AmB alone. The cost-effectiveness and accessibility of PIs in resource-limited geographical areas compared to other antifungal agents, such as flucytosine, make them an appealing choice for combination therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, United States of America.
- Center for One Health Research, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, United States of America.
- Department of Microbiology and Immunology, Faculty of Pharmacy, Zagazig University, Zagazig, Alsharkia, Egypt.
ORCID-Profile: Nour M Alkashef, Mohamed N Seleem
Förderung
- NIAID NIH HHS
- National Institutes of Health
Zitieren
APA
Alkashef, N. M., & Seleem, M. N. (2024). Novel combinatorial approach: Harnessing HIV protease inhibitors to enhance amphotericin B’s antifungal efficacy in cryptococcosis. PLOS ONE. https://doi.org/10.1371/journal.pone.0308216
Vancouver
Alkashef NM, Seleem MN. Novel combinatorial approach: Harnessing HIV protease inhibitors to enhance amphotericin B’s antifungal efficacy in cryptococcosis. PLOS ONE. 2024. doi:10.1371/journal.pone.0308216
BibTeX
@article{Alkashef2024,
author = {Alkashef, Nour M and Seleem, Mohamed N},
title = {Novel combinatorial approach: Harnessing HIV protease inhibitors to enhance amphotericin B’s antifungal efficacy in cryptococcosis},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0308216}
}
EUVIMED